psoriasis

News

AbbVie's psoriasis drug Skyrizi approved in Japan

AbbVie’s hotly anticipated psoriasis drug Skyrizi (risankizumab) has been approved in Japan, the first country to okay this potential blockbuster.

News

Novartis makes quality of life case for Cosentyx with new da...

There is increasing recognition that skin clearance scores may not be enough to win over patients and doctors when it comes to the highly competitive market for psoriasis drugs, even though

News

J&J's Tremfya outperforms Novartis' Cosentyx in psoriasis

A large head-to-head study has shown Johnson & Johnson’s psoriasis drug Tremfya outperformed Novartis’ rival, Cosentyx, which had previously set standards in moderate to severe disease.

News

NICE okays UCB's Cimzia, nixes Almirall's Ilumetri, in psori...

NICE has recommended in draft guidance that UCB’s Cimzia can receive regular NHS funding for plaque psoriasis, but decided that Almirall’s rival Ilumetri does not represent good value for m

News